Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …

Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in
parallel with obesity and type 2 diabetes. Aim To review the global epidemiology of NAFLD …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

There is substantial debate about the intrinsic relationship between insulin resistance, the
metabolic syndrome (MetS) and nonalcoholic fatty liver disease (NAFLD). While NAFLD has …

Das Fortschreiten einer NASH ist assoziiert mit Leberzellstress, konsekutiver Entzündung
und Fibrose, mit potentieller Entwicklung einer Leberzirrhose, portaler Hypertension und der …

Nonalcoholic fatty liver disease (NAFLD) defines fat accumulation in the liver, and it is
commonly associated with metabolic syndromes like diabetes and obesity. Progressive …

Abstract Background & Aims Liver stiffness is an indirect marker of liver fibrosis, which
predicts clinical outcomes in patients with nonalcoholic fatty liver disease (NAFLD). The aim …

Context Ellagic acid (EA) is used in traditional medicine to treated hyperlipidaemia.
Objective This study examined if AMPK mediates the anti-steatotic effect of ellagic acid (EA) …